Affinage

MASP2

Mannan-binding lectin serine protease 2 · UniProt O00187

Length
686 aa
Mass
75.7 kDa
Annotated
2026-04-28
100 papers in source corpus 20 papers cited in narrative 20 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

MASP-2 is the key effector serine protease of the lectin complement pathway, cleaving C4 and C2 to assemble the C3 convertase C4bC2a on pathogen surfaces and damaged host tissues. MASP-2 is exclusively activated by MASP-1 through transactivation within MBL- or ficolin-bridged heterodimeric co-complexes that form via Ca²⁺-dependent CUB1-EGF-CUB2 dimerization, and its catalytic engagement of C4 requires cooperative binding across the CCP1-CCP2-SP domains (PMID:22691502, PMID:23785123, PMID:22071314). Its activity is regulated by C1-inhibitor, which inhibits MASP-2 50-fold faster than C1s, and by TFPI via its Kunitz-2 domain; an alternative splice product, MAp19, shares the CUB1-EGF domains but does not significantly inhibit MASP-2-dependent complement activation at physiological concentrations (PMID:17709141, PMID:25359215, PMID:21871896). MASP-2-dependent lectin pathway activation drives ischemia-reperfusion injury in the brain and contributes to endothelial damage in thrombotic microangiopathies and vaso-occlusion in sickle cell disease (PMID:27577570, PMID:32681658, PMID:35878790).

Mechanistic history

Synthesis pass · year-by-year structured walk · 11 steps
  1. 1999 High

    Molecular cloning established that a single MASP-2 gene encodes both the full-length serine protease and a truncated splice variant (MAp19/sMAP) sharing CUB1-EGF domains, resolving the genetic origin and domain organization of the lectin pathway protease.

    Evidence cDNA cloning and sequence analysis in human, rat, and mouse with tissue expression profiling confirming liver-restricted synthesis

    PMID:10330290 PMID:10586086

    Open questions at the time
    • Regulatory mechanisms controlling alternative splicing of MASP-2 vs. MAp19 not defined
    • Post-translational processing steps not characterized
  2. 2002 High

    The complete domain architecture of MASP-2 (CUB1-EGF-CUB2-CCP1-CCP2-SP) was mapped and its exclusive role in cleaving C4 and C2 to form the C3 convertase was confirmed, distinguishing it functionally from MASP-1 and MASP-3.

    Evidence Molecular cloning, sequence comparison with C1r/C1s family members, and functional complement assays

    PMID:12396007

    Open questions at the time
    • Structural basis for differential substrate recognition vs. C1s not resolved
  3. 2004 High

    Enzymatic characterization defined MASP-2's substrate specificity—high activity toward native C4 but low activity on small fluorescent substrates—and identified C1-inhibitor as its physiological regulator, while crystal structure of MAp19 at 2.5 Å revealed the CUB1-domain residues critical for MBL/ficolin binding.

    Evidence In vitro cleavage assays with recombinant MASPs, serpin inhibition kinetics, X-ray crystallography of MAp19 with site-directed mutagenesis and SPR

    PMID:14725788 PMID:15117939

    Open questions at the time
    • Full-length MASP-2 structure in complex with C4 not determined
    • Whether MAp19 has an independent biological function beyond MBL binding remained open
  4. 2006 High

    Reconstitution experiments demonstrated that MASP-1 and MASP-2 cooperate synergistically in C3 convertase generation through the lectin pathway, with MASP-3 acting as an inhibitor, establishing the functional hierarchy among MASPs.

    Evidence Complement depletion and reconstitution assays measuring C3b deposition on mannan-coated surfaces

    PMID:17182967

    Open questions at the time
    • Whether MASP-1's role was direct activation of MASP-2 or parallel C2 cleavage was not yet distinguished
  5. 2007 High

    Substrate phage display and kinetic analysis revealed that MASP-2 is up to 1000-fold more catalytically active than C1s toward C2 and C4 cleavage sequences, and that C1-inhibitor inhibits MASP-2 50-fold faster than C1s, redefining MASP-2 as the major physiological target of this serpin in complement regulation.

    Evidence Randomized substrate phage display, peptide cleavage assays, serpin inhibition kinetics

    PMID:17709141

    Open questions at the time
    • In vivo contribution of C1-inhibitor to MASP-2 regulation vs. other serpins not quantified
  6. 2011 High

    Domain-mapping experiments established that MASP-2's CCP1-CCP2-SP domains cooperate for high-affinity C4 binding and that K342 in CCP1 is essential, while quantitative serum measurements showed MAp19 does not inhibit MASP-2 complement activity at physiological concentrations, correcting prior claims.

    Evidence Binding assays with domain deletion constructs and site-directed mutagenesis; quantitative ELISA, complement activation assays, immunohistochemistry

    PMID:21871896 PMID:22071314

    Open questions at the time
    • Full structural model of MASP-2–C4 interface not available
    • Biological function of circulating and urinary MAp19 unknown
  7. 2012 High

    Using monospecific inhibitors in human serum, MASP-1 was identified as the exclusive physiological activator of MASP-2, resolving the long-standing question of whether MASP-2 can autoactivate in vivo.

    Evidence Monospecific MASP-1 and MASP-2 inhibitors in functional lectin pathway activation assays in normal human serum

    PMID:22691502

    Open questions at the time
    • Whether MASP-2 can autoactivate under any non-physiological or pathological condition remains untested
  8. 2013 High

    The structural basis for MASP-1–MASP-2 transactivation was elucidated: MBL/ficolins bridge Ca²⁺-dependent CUB1-EGF-CUB2 heterodimers that enable MASP-1 to directly cleave MASP-2, and MAp44 disrupts these co-complexes as an endogenous inhibitor.

    Evidence Native PAGE, SEC, Ca²⁺-dependent subunit exchange experiments, and complement activation assays with MAp44 inhibition

    PMID:23785123 PMID:24424083

    Open questions at the time
    • Stoichiometry and architecture of native MBL-MASP co-complexes on target surfaces not resolved
    • Quantitative contribution of MAp44 regulation in vivo not measured
  9. 2014 High

    TFPI was identified as a selective physiological inhibitor of MASP-2 that does not affect MASP-1 or classical pathway proteases, with the Kunitz-2 domain mediating this specificity—establishing a cross-talk mechanism between coagulation and lectin pathway regulation.

    Evidence Ex vivo C4-deposition assay, chromogenic MASP-2 activity assay, domain-specific monoclonal antibody blocking of TFPI

    PMID:25359215

    Open questions at the time
    • In vivo relevance of TFPI–MASP-2 inhibition not validated in animal models
    • Whether TFPI regulation of MASP-2 affects coagulation parameters not tested
  10. 2016 High

    MASP-2 was demonstrated to be the critical driver of cerebral ischemia-reperfusion injury, as MASP-2-knockout mice showed reduced infarct volumes and neuroinflammation while MASP-1/3-knockout mice were unprotected, establishing a MASP-1-independent pathogenic role for MASP-2 in stroke.

    Evidence Genetic knockout mice (MASP-2⁻/⁻, MASP-1/3⁻/⁻) in tMCAO and 3VO stroke models with histopathological, immunohistochemical, and behavioral readouts

    PMID:27577570

    Open questions at the time
    • MASP-1-independent activation mechanism of MASP-2 in this setting not explained
    • Whether MASP-2 acts via C3 convertase or alternative substrates in neuroinflammation not distinguished
  11. 2020 Medium

    Lectin pathway-dependent endothelial injury in thrombotic microangiopathies and sickle cell vaso-occlusion was shown to depend on MASP-2, as anti-MASP-2 antibodies suppressed caspase-8 activation in endothelial cells exposed to TMA plasmas and reduced complement deposition, inflammation, and microvascular stasis in sickle cell mice.

    Evidence In vitro MVEC caspase-8 assay with narsoplimab and patient plasmas; in vivo Townes SS mouse model with MASP-2 inhibitory mAbs, intravital microscopy, ELISA

    PMID:32681658 PMID:35878790

    Open questions at the time
    • Downstream signaling pathway from MASP-2 to endothelial caspase-8 not defined
    • Clinical efficacy of MASP-2 inhibition in human TMA/SCD not established by these studies
    • Single-lab findings for each disease model

Open questions

Synthesis pass · forward-looking unresolved questions
  • Key unresolved questions include the full structural basis of the MASP-2–C4 complex, the MASP-1-independent activation mechanism observed in ischemia-reperfusion, the biological function of MAp19, and whether MASP-2 cleaves non-complement substrates that contribute to its pathogenic roles.
  • No crystal structure of MASP-2 in complex with C4
  • MAp19 function remains unknown
  • Non-complement substrates of MASP-2 not systematically profiled

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140096 catalytic activity, acting on a protein 6 GO:0016787 hydrolase activity 3
Localization
GO:0005576 extracellular region 3 GO:0005829 cytosol 1
Pathway
R-HSA-168256 Immune System 6 R-HSA-1643685 Disease 3
Partners
C2C4FCN1FCN2MASP1MBL2SERPING1TFPI
Complex memberships
Ficolin-MASP complexMBL-MASP complex

Evidence

Reading pass · 20 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2012 In normal human serum, MASP-2 activation strictly depends on MASP-1; MASP-1 acts as the exclusive activator of MASP-2, and inhibition of MASP-1 prevents autoactivation of MASP-2. Furthermore, MASP-1 produces 60% of C2a responsible for C3 convertase formation. Monospecific inhibitors against MASP-1 and MASP-2 used in functional complement activation assays in human serum Proceedings of the National Academy of Sciences of the United States of America High 22691502
1999 MASP-2 is encoded by the MASP-2 gene and a truncated form (sMAP/MAp19) is produced by alternative polyadenylation using a sMAP-specific exon with an in-frame stop codon; MAp19 consists of the first two domains of MASP-2 (CUB1 and EGF-like) plus four additional C-terminal amino acids and is a component of the MBL-MASP complex. cDNA cloning, sequence analysis, and biochemical characterization of MBL-MASP complex components International immunology High 10330290
2004 MASP-2 cleaves complement components C4 and C2 to form the C3 convertase C4b2a; its substrate specificity differs from MASP-1, with MASP-2 showing very low activity against fluorescent amide substrates but efficiently cleaving C4 as a natural protein substrate. C1-inhibitor inhibits both MASP-1 and MASP-2. In vitro cleavage assays using recombinant and serum-derived MASPs with fluorescent amide substrates and natural protein substrates; inhibitor profiling Molecular immunology High 14725788
2007 MASP-2 substrate specificity requires P1 position and S2/S3 subsites (Gly at P2, hydrophobic at P3); MASP-2 is up to 1000 times more catalytically active than C1s toward C2, C4, and C1-inhibitor cleavage sequences; C1-inhibitor inhibits MASP-2 50-fold faster than C1s, identifying MASP-2 as a major physiological target of C1-inhibitor. Randomized substrate phage display library, peptide substrate cleavage assays, serpin inhibition kinetics Molecular immunology High 17709141
2004 X-ray crystal structure of MAp19 (the alternative splice product of MASP-2) resolved to 2.5 Å reveals a head-to-tail homodimer stabilized by Ca2+ ions; point mutations at Tyr59, Asp60, Glu83, Asp105, Tyr106, and Glu109 in the CUB1 module abolish or strongly decrease interaction with MBL and L-ficolin, defining the common binding site. X-ray crystallography (2.5 Å resolution) and surface plasmon resonance with point mutants The Journal of biological chemistry High 15117939
2000 MASP-1, MASP-2, and MAp19 are found exclusively associated with MBL in serum (not with C1q); C1r and C1s associate exclusively with C1q (not MBL); the MASPs and MAp19 require both high salt and calcium chelation (EDTA) to fully dissociate from MBL; the bulk of MASP-1 and MAp19 circulates as large complexes not bound to MBL. Serum fractionation, gel-permeation chromatography, complement activation assays in C1r-deficient serum Journal of immunology High 10878362
2011 MAp19 does not compete with MASP-2 for binding to MBL at physiological concentrations, nor does it inhibit MASP-2-mediated complement activation; both MASP-2 and MAp19 are predominantly expressed in hepatocytes; high levels of MAp19 are found in urine where MASP-2 is absent. Quantitative ELISA with monoclonal antibodies, complement activation assays, immunohistochemistry, qRT-PCR Journal of immunological methods High 21871896
2006 MASP-1 cooperates with MASP-2 in generating the C3 convertase through the MBL pathway; depletion of MASP-1, MASP-2, and MASP-3 abolishes C3b deposition on mannan, and reconstitution with both MASP-1 and MASP-2 shows synergistic effect; MASP-3 inhibits this process; the cooperation requires C4 and C2 but not factor B. Complement depletion and reconstitution assays measuring C3b deposition on mannan-coated surfaces International immunology High 17182967
2013 MASP-1 and MASP-2 form heterodimeric co-complexes when bridged by MBL or ficolins; these co-complexes have a functional role in complement activation; MAp44 may inhibit complement by disrupting MASP-1–MASP-2 co-complexes and thereby impairing MASP-1-mediated transactivation of MASP-2. Native PAGE, size exclusion chromatography, complement activation assays, and inhibition studies with MAp44 Journal of immunology High 23785123
2011 MASP-2 requires multiple domains for high-affinity interaction with its substrate C4: the CCP1-CCP2-SP combination binds C4 with much higher affinity than CCP1-CCP2 or SP domain alone, indicating cooperative interaction; mutation of K342A in CCP1 abolishes binding to C4 and C4b. Binding assays with active and catalytically inactive recombinant MASP-2 domain constructs; site-directed mutagenesis Molecular immunology High 22071314
1999 Rat and mouse MASP-2 are components of the MBL lectin pathway activation complex; both MASP-2 and MAp19 are encoded by a single structural MASP-2 gene (as in humans) and are exclusively synthesized in the liver; rat MASP-2 cleaves complement component C4. cDNA cloning, Southern blot, PCR, hepatic biosynthesis demonstrated by tissue expression analysis, C4 cleavage assay Journal of immunology High 10586086
2006 Carp MASP2 associates with MBL homologs and cleaves native human C4 into C4b (but not C4i with hydrolyzed thioester), demonstrating that MASP2 and its C4-cleaving function arose before the emergence of bony fish. Protein isolation, molecular cloning, phylogenetic analysis, C4 cleavage activity assay Journal of immunology Medium 17015733
2016 MASP-2 critically mediates cerebral ischemia-reperfusion injury independently of MASP-1: MASP-2-deficient mice show significantly reduced neurological deficits, infarct volumes, C3 deposition, and pro-inflammatory microglia phenotype after transient ischemia, while MASP-1/3-deficient mice are not protected. Genetic knockout mice (MASP-2−/−, MASP-1/3−/−, fB−/−) and inhibitory antibody in tMCAO/3VO stroke models; immunohistochemistry, behavioral, and histopathological assessment Journal of neuroinflammation High 27577570
2014 Tissue factor pathway inhibitor (TFPI) selectively inhibits MASP-2 activity without affecting MASP-1 or classical pathway proteases C1s/C1r; the Kunitz-2 domain of TFPI is required for this inhibition, as demonstrated by domain-specific antibody blocking. Ex vivo lectin pathway C4-deposition assay, fluid-phase chromogenic MASP-2 activity assay, domain-specific monoclonal antibody blocking European journal of immunology High 25359215
2014 MASP-1 and MASP-2 CUB1-EGF-CUB2 fragments form Ca2+-dependent homodimers that can exchange subunits to form MASP-1:MASP-2 heterodimers after dissociation/re-association, providing structural basis for the co-complex formation required for transactivation. Size exclusion chromatography, native PAGE, EDTA dissociation and re-calcification reassociation experiments with recombinant domain fragments Molecular immunology Medium 24424083
2019 MASP-2 variants G634R and R203W in human patients cause functional defects including reduced (R203W) or abolished (G634R) protein secretion, loss of capability to cleave MASP-2 precursor into its active form (G634R), and reduced antiviral activity in vivo; MBL-deficient mice have decreased survival and increased HSV-1 brain burden, linking MASP-2 function to protection against herpes simplex encephalitis. In vitro expression of variant proteins assessing secretion and autoactivation cleavage; murine HSE model with MBL-deficient mice PLoS pathogens Medium 31869396
2005 Mouse ficolin A and its splicing variant, but not ficolin B, bind MASP-2 and form complexes with potent complement-activating capacity; sMAP (MAp19) competes with MASP-2 for association with ficolin A and inhibits complement activation by the ficolin A/MASP-2 complex, indicating a regulatory role for MAp19. Recombinant protein expression, binding assays, and complement activation assays Immunogenetics Medium 16328467
2002 MASP-2 shares identical domain structure with MASP-1, MASP-3, C1r, and C1s (comprising CUB1-EGF-CUB2-CCP1-CCP2-serine protease domains); MASP-2 is the protease responsible for activating C4 and C2 to generate the C3 convertase C4bC2b; MASP-1 and MASP-3 are alternative splice products of the MASP1/3 gene, while MASP-2 and MAp19 are alternative products of the MASP-2 gene. Molecular cloning, sequence analysis, and functional complement assays Immunobiology High 12396007
2020 MASP-2 (the effector enzyme of the lectin pathway) is elevated in thrombotic microangiopathies; plasmas from TMA patients induce microvascular endothelial cell caspase 8 activation, which is suppressed by the anti-MASP-2 antibody narsoplimab, demonstrating that MASP-2-mediated lectin pathway activation directly contributes to endothelial injury in TMAs. ELISA for MASP-2 levels, in vitro MVEC caspase 8 activity assay with patient plasmas and narsoplimab inhibition Clinical and experimental immunology Medium 32681658
2022 MASP-2 and MASP-3 inhibitory monoclonal antibodies markedly reduce complement activation (Bb, C4d, C5a, complement deposition in liver/kidney/lung), hepatic inflammation markers (NF-κB, VCAM-1, ICAM-1, E-selectin), and microvascular stasis (vaso-occlusion) in sickle cell disease mice after hypoxia-reoxygenation or hemoglobin challenge. In vivo mouse model (Townes SS mice) with MASP-2 and MASP-3 inhibitory mAbs, intravital microscopy for microvascular stasis, ELISA and immunohistochemistry for complement markers Translational research Medium 35878790

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
1988 Insulin-stimulated MAP-2 kinase phosphorylates and activates ribosomal protein S6 kinase II. Nature 1005 2842685
1992 The role of microtubule-associated protein 2 (MAP-2) in neuronal growth, plasticity, and degeneration. Journal of neuroscience research 310 1484385
1980 Structure and phosphorylation of microtubule-associated protein 2 (MAP 2). Proceedings of the National Academy of Sciences of the United States of America 257 6251448
1981 A protein kinase bound to the projection portion of MAP 2 (microtubule-associated protein 2). The Journal of cell biology 232 6270156
1983 Association of microtubule-associated protein 2 (MAP 2) with microtubules and intermediate filaments in cultured brain cells. The Journal of cell biology 188 6343400
1994 DLX-2, MASH-1, and MAP-2 expression and bromodeoxyuridine incorporation define molecularly distinct cell populations in the embryonic mouse forebrain. The Journal of neuroscience : the official journal of the Society for Neuroscience 185 7965042
2012 Revised mechanism of complement lectin-pathway activation revealing the role of serine protease MASP-1 as the exclusive activator of MASP-2. Proceedings of the National Academy of Sciences of the United States of America 163 22691502
1991 ERKs, extracellular signal-regulated MAP-2 kinases. Current opinion in cell biology 142 1667578
1999 A truncated form of mannose-binding lectin-associated serine protease (MASP)-2 expressed by alternative polyadenylation is a component of the lectin complement pathway. International immunology 140 10330290
2020 Safety, Tolerability and Efficacy of Narsoplimab, a Novel MASP-2 Inhibitor for the Treatment of IgA Nephropathy. Kidney international reports 127 33163724
1990 The tubulin-binding sequence of brain microtubule-associated proteins, tau and MAP-2, is also involved in actin binding. The Biochemical journal 125 2115775
2004 Differential substrate and inhibitor profiles for human MASP-1 and MASP-2. Molecular immunology 113 14725788
2005 Altered expression of MAP-2, GAP-43, and synaptophysin in the hippocampus of rats with chronic cerebral hypoperfusion correlates with cognitive impairment. Brain research. Molecular brain research 111 15964096
2021 hu.MAP 2.0: integration of over 15,000 proteomic experiments builds a global compendium of human multiprotein assemblies. Molecular systems biology 98 33973408
2002 The mannan-binding lectin-associated serine proteases (MASPs) and MAp19: four components of the lectin pathway activation complex encoded by two genes. Immunobiology 96 12396007
1998 Disruption of MAP-2 immunostaining in rat hippocampus after traumatic brain injury. Journal of neurotrauma 91 9605349
2000 Interaction of C1q and mannan-binding lectin (MBL) with C1r, C1s, MBL-associated serine proteases 1 and 2, and the MBL-associated protein MAp19. Journal of immunology (Baltimore, Md. : 1950) 89 10878362
1987 An immunocytochemical analysis of the ontogeny of the microtubule-associated proteins MAP-2 and Tau in the nervous system of the rat. Brain research 82 3113673
1998 Making sense of the multiple MAP-2 transcripts and their role in the neuron. Molecular neurobiology 74 9588626
2006 Cooperation between MASP-1 and MASP-2 in the generation of C3 convertase through the MBL pathway. International immunology 73 17182967
1995 Abnormal expression of microtubule-associated protein 2 (MAP-2) in neocortex in Rett syndrome. Neuropediatrics 66 7566447
2007 Elucidation of the substrate specificity of the MASP-2 protease of the lectin complement pathway and identification of the enzyme as a major physiological target of the serpin, C1-inhibitor. Molecular immunology 65 17709141
1993 Ammonium injection induces an N-methyl-D-aspartate receptor-mediated proteolysis of the microtubule-associated protein MAP-2. Journal of neurochemistry 65 8473887
1998 Complex formation of SMAP/KAP3, a KIF3A/B ATPase motor-associated protein, with a human chromosome-associated polypeptide. The Journal of biological chemistry 63 9506951
1996 SMAP, an Smg GDS-associating protein having arm repeats and phosphorylated by Src tyrosine kinase. The Journal of biological chemistry 60 8900189
2011 MAp19, the alternative splice product of the MASP2 gene. Journal of immunological methods 59 21871896
1994 Antisense MAP-2 oligonucleotides induce changes in microtubule assembly and neuritic elongation in pre-existing neurites of rat cortical neurons. Cell motility and the cytoskeleton 57 8020109
1986 Identification of a MAP 2-like ATP-binding protein associated with axoplasmic vesicles that translocate on isolated microtubules. The Journal of cell biology 57 3091608
1997 Calcium-stimulated phosphorylation of MAP-2 in pancreatic betaTC3-cells is mediated by Ca2+/calmodulin-dependent kinase II. The Journal of biological chemistry 55 9341200
1989 Cell cycle-dependent changes in the dynamics of MAP 2 and MAP 4 in cultured cells. The Journal of cell biology 51 2745548
2013 Co-complexes of MASP-1 and MASP-2 associated with the soluble pattern-recognition molecules drive lectin pathway activation in a manner inhibitable by MAp44. Journal of immunology (Baltimore, Md. : 1950) 50 23785123
2006 Lectin pathway of bony fish complement: identification of two homologs of the mannose-binding lectin associated with MASP2 in the common carp (Cyprinus carpio). Journal of immunology (Baltimore, Md. : 1950) 50 17015733
2012 MBL2, MASP2, AMELX, and ENAM gene polymorphisms and dental caries in Polish children. Oral diseases 49 22221294
2004 The X-ray structure of human mannan-binding lectin-associated protein 19 (MAp19) and its interaction site with mannan-binding lectin and L-ficolin. The Journal of biological chemistry 49 15117939
1990 Ganglioside-enhanced neurite growth: evidence for a selective induction of high-molecular-weight MAP-2. The Journal of neuroscience : the official journal of the Society for Neuroscience 49 2153774
2020 MASP2 levels are elevated in thrombotic microangiopathies: association with microvascular endothelial cell injury and suppression by anti-MASP2 antibody narsoplimab. Clinical and experimental immunology 48 32681658
2016 Mannan binding lectin-associated serine protease-2 (MASP-2) critically contributes to post-ischemic brain injury independent of MASP-1. Journal of neuroinflammation 48 27577570
1997 Co-expression of MAP-2 and GFAP in cells developing from rat EGF responsive precursor cells. Brain research. Developmental brain research 48 9051273
2005 Carbohydrate-binding specificities of mouse ficolin A, a splicing variant of ficolin A and ficolin B and their complex formation with MASP-2 and sMAP. Immunogenetics 47 16328467
2011 Characterization of schistosome tegumental alkaline phosphatase (SmAP). PLoS neglected tropical diseases 46 21483710
1995 Degradation of fodrin and MAP 2 after neonatal cerebral hypoxic-ischemia. Brain research 46 7583214
1995 Microtubule-associated protein 2 (MAP-2): a sensitive marker of seizure-related brain damage. Journal of neuroscience methods 46 8618422
1985 Microheterogeneity of microtubule-associated proteins, MAP-1 and MAP-2, and differential phosphorylation of individual subcomponents. The Journal of biological chemistry 46 2985613
2014 Mannose-Binding Lectin (MBL) and MBL-associated serine protease-2 (MASP-2) in women with malignant and benign ovarian tumours. Cancer immunology, immunotherapy : CII 44 25038892
2010 SMAP-WS: a parallel web service for structural proteome-wide ligand-binding site comparison. Nucleic acids research 44 20484373
2022 Cardio-facio-cutaneous syndrome and gastrointestinal defects: report on a newborn with 19p13.3 deletion including the MAP 2 K2 gene. Italian journal of pediatrics 42 35509048
1985 Analysis of the microtubule-binding domain of MAP-2. The Journal of cell biology 42 4055896
1986 The binding of MAP-2 and tau on brain microtubules in vitro: implications for microtubule structure. Annals of the New York Academy of Sciences 40 3089106
2015 Plasma levels of mannan-binding lectin-associated serine proteases MASP-1 and MASP-2 are elevated in type 1 diabetes and correlate with glycaemic control. Clinical and experimental immunology 36 25533914
2024 Diagnostic Performance of GFAP, UCH-L1, and MAP-2 Within 30 and 60 Minutes of Traumatic Brain Injury. JAMA network open 34 39230905
2002 MAP-2e, a novel MAP-2 isoform, is expressed in gliomas and delineates tumor architecture and patterns of infiltration. Journal of neuropathology and experimental neurology 34 12025943
1995 Non-cooperative binding of the MAP-2 microtubule-binding region to microtubules. The Journal of biological chemistry 34 7836356
2014 TFPI inhibits lectin pathway of complement activation by direct interaction with MASP-2. European journal of immunology 33 25359215
1991 Activation of MAP-2 kinase activity by the CD2 receptor in Jurkat T cells can be reversed by CD45 phosphatase. Immunology 33 1676984
2015 Impact of MBL and MASP-2 gene polymorphism and its interaction on susceptibility to tuberculosis. BMC infectious diseases 31 25887173
2011 MASP2 gene polymorphism is associated with susceptibility to hepatitis C virus infection. Human immunology 31 21843573
1983 Characterisation of microtubule-associated proteins at the synapse: absence of MAP 2. European journal of cell biology 31 11596488
2000 Systemic hypothermia following spinal cord compression injury in the rat: an immunohistochemical study on MAP 2 with special reference to dendrite changes. Acta neuropathologica 29 11045677
2005 Cloning, cellular localization, genomic organization, and tissue-specific expression of the TGFbeta1-inducible SMAP-5 gene. Gene 28 15922870
1989 Sequence of a human MAP-2 region sharing epitopes with Alzheimer neurofibrillary tangles. Journal of neuroscience research 28 2481044
1988 Microtubule-associated protein 2 (MAP 2) immunoreactivity in human fetal neocortex. Brain research 28 3293702
2009 Mannan-binding lectin-associated serine protease-2 (MASP-2) in a large cohort of neonates and its clinical associations. Molecular immunology 27 19307021
2005 Expression of SMAP-29 cathelicidin-like peptide in bacterial cells by intein-mediated system. Protein expression and purification 27 15642466
1998 MASP-2, the C3 convertase generating protease of the MBLectin complement activating pathway. Immunobiology 27 9777418
1999 The rat and mouse homologues of MASP-2 and MAp19, components of the lectin activation pathway of complement. Journal of immunology (Baltimore, Md. : 1950) 26 10586086
2022 MASP-2 and MASP-3 inhibitors block complement activation, inflammation, and microvascular stasis in a murine model of vaso-occlusion in sickle cell disease. Translational research : the journal of laboratory and clinical medicine 25 35878790
2008 MBL2 and MASP2 gene polymorphisms in patients with hepatocellular carcinoma. Journal of viral hepatitis 25 18221301
2001 Molecular cloning of the complement (C1r/C1s/MASP2-like serine proteases from the common carp (Cyprinus carpio). Immunogenetics 25 11220628
1998 cFKBP/SMAP; a novel molecule involved in the regulation of smooth muscle differentiation. Development (Cambridge, England) 25 9716519
1980 High molecular weight protein MAP 2 promoting microtubule assembly in vitro is associated with microtubules in cells. Cell biology international reports 25 7438221
2005 Novel MASP2 variants detected among North African and Sub-Saharan individuals. Tissue antigens 24 16029433
2011 Mannan-binding lectin (MBL) and MBL-associated serine protease 2 (MASP-2) genotypes in colorectal cancer. Scandinavian journal of immunology 23 21198752
2003 Diagnostic value of microtubule-associated protein-2 (MAP-2) for neuroendocrine neoplasms. Advances in anatomic pathology 23 12605092
2019 Herpes simplex encephalitis in adult patients with MASP-2 deficiency. PLoS pathogens 21 31869396
1992 Dietary aluminum selectively decreases MAP-2 in brains of developing and adult rats. Neurotoxicology 21 1331920
1989 Alz-50 immunoreactivity in the neonatal rat: changes in development and co-distribution with MAP-2 immunoreactivity. Neuroscience letters 21 2657503
2019 Should MASP-2 Deficiency Be Considered a Primary Immunodeficiency? Relevance of the Lectin Pathway. Journal of clinical immunology 20 31828694
2018 Detrimental Effects of Helium Ion Irradiation on Cognitive Performance and Cortical Levels of MAP-2 in B6D2F1 Mice. International journal of molecular sciences 20 29677125
2013 Leprosy association with low MASP-2 levels generated by MASP2 haplotypes and polymorphisms flanking MAp19 exon 5. PloS one 20 23935922
2011 Multiple domains of MASP-2, an initiating complement protease, are required for interaction with its substrate C4. Molecular immunology 20 22071314
2008 Association of Gap-43 (neuromodulin) with microtubule-associated protein MAP-2 in neuronal cells. Biochemical and biophysical research communications 20 18455509
2002 Microtubule-associated protein 2 (MAP-2) is expressed in low and high grade diffuse astrocytomas. Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 20 11922706
1995 Diminished expression of microtubule-associated protein (MAP-2) and beta-tubulin as a putative marker for ischemic injury in neocortical transplants. Cell transplantation 20 7728337
2021 Targeting the Complement Serine Protease MASP-2 as a Therapeutic Strategy for Coronavirus Infections. Viruses 19 33671334
2019 Schistosomes can hydrolyze proinflammatory and prothrombotic polyphosphate (polyP) via tegumental alkaline phosphatase, SmAP. Molecular and biochemical parasitology 19 31154018
2013 Bacterial killing mechanism of sheep myeloid antimicrobial peptide-18 (SMAP-18) and its Trp-substituted analog with improved cell selectivity and reduced mammalian cell toxicity. Amino acids 19 24221355
2011 Multiplex sequence-specific polymerase chain reaction reveals new MASP2 haplotypes associated with MASP-2 and MAp19 serum levels. Human immunology 19 21683108
2007 Genetic influences on mannan-binding lectin (MBL) and mannan-binding lectin associated serine protease-2 (MASP-2) activity. Genetic epidemiology 19 17096357
2014 Dissociation and re-association studies on the interaction domains of mannan-binding lectin (MBL)-associated serine proteases, MASP-1 and MASP-2, provide evidence for heterodimer formation. Molecular immunology 18 24424083
2013 Calretinin and microtubule-associated protein-2 (MAP-2) immunohistochemistry in the diagnosis of Hirschsprung's disease. Journal of pediatric surgery 18 24094966
2012 Mutations of complement lectin pathway genes MBL2 and MASP2 associated with placental malaria. Malaria journal 18 22380611
2009 Utility of microtubule associated protein-2 (MAP-2) immunohistochemistry for identification of ganglion cells in paraffin-embedded rectal suction biopsies. The American journal of surgical pathology 18 19363440
2009 Lack of association between polymorphisms of MASP2 and susceptibility to SARS coronavirus infection. BMC infectious diseases 18 19405982
2022 Methyltransferase-like (METTL)14-mediated N6-methyladenosine modification modulates retinal pigment epithelial (RPE) activity by regulating the methylation of microtubule-associated protein (MAP)2. Bioengineered 17 35139773
2016 Experimentally-induced anti-myeloperoxidase vasculitis does not require properdin, MASP-2 or bone marrow-derived C5. The Journal of pathology 17 27235854
2014 Overexpression of MAP-2 via formation of microtubules plays an important role in the sprouting of mossy fibers in epileptic rats. Journal of molecular neuroscience : MN 17 24390958
2014 Association of MASP2 polymorphisms and protein levels with rheumatic fever and rheumatic heart disease. Human immunology 16 25318078
2009 Genetic and structural analysis of MBL2 and MASP2 polymorphisms in south-eastern African children. Tissue antigens 16 19775369
2006 Involvement of a novel ADP-ribosylation factor GTPase-activating protein, SMAP, in membrane trafficking: implications in cancer cell biology. Cancer science 16 16805823
1998 Involvement of stromal membrane-associated protein (SMAP-1) in erythropoietic microenvironment. Journal of biochemistry 16 9644265